IZI Medical has acquired Naslund Medical, a recognized innovator in premium fiducial marker solutions used in radiation oncology. The addition of Gold Anchor strengthens IZI’s position in a clinically important and fast-growing segment of cancer treatment. Together with our existing Visicoil platform, the combined portfolio establishes IZI as a leading provider of premium fiducial markers globally.
About Naslund Medical and Gold Anchor
Naslund Medical AB is a Swedish medical technology company specializing in innovative medical products designed to improve the management and treatment of cancer patients. The company markets Gold Anchor, an implantable soft-tissue fiducial marker used worldwide.
Gold Anchor combines minimally invasive marker implantation, a unique marker design that minimizes migration, and clear visibility across multiple imaging modalities to support faster and more precise radiation therapy, enhance patient safety, and enable accurate image guidance during treatment.
Gold Anchor was invented and developed by Ingemar Näslund, MD, PhD, Associate Professor and former Head of the Division of Radiotherapy at Karolinska University Hospital in Stockholm, Sweden. Dr. Näslund also co-authored the first publication describing the stereotactic body radiation therapy (SBRT) technique, invented together with physicist Associate Professor Ingmar Lax and colleague Associate Professor Henric Blomgren. Today, SBRT is used worldwide and has become a standard treatment option for several tumor types.
Naslund Medical AB is headquartered in Huddinge, Sweden, with subsidiaries in the United States, the United Kingdom, and France, and is supported by a global network of distribution partners.